
Orasure (($OSUR)) has held its Q3 earnings call. Read on for the main highlights of the call. OraSure’s earnings call carried a broadly positive tone as the company returned to
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OSUR | Orasure Technologies | 3.46 | 1.19 | 52.42% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.46 | +52.42% |

Orasure (($OSUR)) has held its Q3 earnings call. Read on for the main highlights of the call. OraSure’s earnings call carried a broadly positive tone as the company returned to

Orasure (OSUR) is scheduled to report 3rd quarter earnings on 11/09/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Orasure to post earnings of -$0.21 per share.

As previously reported, Craig-Hallum initiated coverage of OraSure (OSUR) with a Buy rating and $7 price target The firm believes Q3 is an inflection point that should be a catalyst

Craig-Hallum initiated coverage of OraSure (OSUR) with a Buy rating and $7 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Orasure (($OSUR)) has held its Q2 earnings call. Read on for the main highlights of the call. OraSure’s latest earnings call struck a cautiously upbeat tone as management balanced solid

Orasure (OSUR) is scheduled to report 2nd quarter earnings on 08/05/2026, after the market closes. Regarding Q2 estimates, Wall Street analysts expect Orasure to post earnings of -$0.27 per share.

OraSure (OSUR) announced that it has received Emergency Use Authorization from the FDA for its second generation OraQuick Ebola 2.0 Rapid Antigen Test for use with whole blood in live

Orasure Technologies ( ($OSUR) ) just unveiled an update. On June 11, 2026, OraSure Technologies, Inc. announced that the U.S. FDA cleared its Colli-Pee Dx Urine Collection Kit from subsidiary

OraSure (OSUR) announced FDA clearance of its Colli-Pee Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche’s (RHHBY) tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas

Orasure Technologies ( ($OSUR) ) has provided an update. At its June 3, 2026 annual meeting, OraSure Technologies’ stockholders approved an amendment and restatement of the company’s 2000 Stock Award
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Initiated | Oct 23, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $249.26M | $-0.17 | $30.87M | -0.01 | -5.23 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.